UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 58

Sortiert nach

Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346)

The Journal of urology, 2012-10, Vol.188 (4), p.1164-1169

2012

Volltextzugriff (PDF)

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

European urology, 2018-06, Vol.73 (6), p.847-855

2018

Volltextzugriff (PDF)

Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction

JAMA oncology, 2017-11, Vol.3 (11), p.e170231

2017

Volltextzugriff (PDF)

Inflammatory Bowel Disease and the Risk of Prostate Cancer

European urology, 2019-05, Vol.75 (5), p.846-852

2019

Volltextzugriff (PDF)

Phase II Evaluation of Early Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel Combined With Hormonal Therapy in Patients With High-risk Metastatic Prostate Adenocarcinoma: Southwest Oncology Group S0032

Urology (Ridgewood, N.J.), 2011-05, Vol.77 (5), p.1172-1176

2011

Volltextzugriff (PDF)

Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer

Current opinion in oncology, 2013-05, Vol.25 (3), p.252-260

2013

Volltextzugriff (PDF)

Educational Material on Prostate Cancer Screening is Overly Complex and Fails to Meet Recommended Layperson Readability Guidelines

Urology (Ridgewood, N.J.), 2020-01, Vol.135, p.1-3

2020

Volltextzugriff (PDF)

The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data

The Journal of urology, 2020-04, Vol.203 (4), p.743-750

2020

Volltextzugriff (PDF)

A Sequential Treatment Approach to Myoinvasive Urothelial Cancer: A Phase II Southwest Oncology Group Trial (S0219)

The Journal of urology, 2009-06, Vol.181 (6), p.2476-2481

2009

Volltextzugriff (PDF)

Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421

Clinical genitourinary cancer, 2017-12, Vol.15 (6), p.635-641

2017

Volltextzugriff (PDF)

A PROSPECTIVE ANALYSIS OF THE TIME TO NORMALIZATION OF SERUM ANDROGENS FOLLOWING 6 MONTHS OF ANDROGEN DEPRIVATION THERAPY IN PATIENTS ON A RANDOMIZED PHASE III CLINICAL TRIAL USING LIMITED HORMONAL THERAPY

The Journal of urology, 2005-05, Vol.173 (5), p.1567-1571

2005

Volltextzugriff (PDF)

A Double-Blind Randomized Crossover Study of Oral Thalidomide Versus Placebo for Androgen Dependent Prostate Cancer Treated With Intermittent Androgen Ablation

The Journal of urology, 2009-03, Vol.181 (3), p.1104-1113

2009

Volltextzugriff (PDF)

Kinetics of Serum Androgen Normalization and Factors Associated With Testosterone Reserve After Limited Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer

The Journal of urology, 2008-10, Vol.180 (4), p.1432-1437

2008

Volltextzugriff (PDF)

Southwest Oncology Group Phase II Study of Ispinesib in Androgen-Independent Prostate Cancer Previously Treated with Taxanes

Clinical genitourinary cancer, 2008-09, Vol.6 (2), p.103-109

2008

Volltextzugriff (PDF)

Integrin alpha2beta1 (α2β1) promotes prostate cancer skeletal metastasis

Clinical & experimental metastasis, 2013-06, Vol.30 (5), p.569-578

2013

Volltextzugriff (PDF)

Innovations and Challenges in Prostate Cancer: Summary Statement for the 6th Cambridge Conference

The Journal of urology, 2007-09, Vol.178 (3), p.S5-S8

2007

Volltextzugriff (PDF)

Phase II Open-Label Study of Oral Piritrexim in Patients with Advanced Carcinoma of the Urothelium Who Have Experienced Failure with Standard Chemotherapy

Clinical genitourinary cancer, 2008-03, Vol.6 (1), p.31-35

2008

Volltextzugriff (PDF)

PD18-02 INCREASED URINARY VASCULAR ENDOTHELIAL GROWTH FACTOR D (VEGF-D) LEVELS ARE ASSOCIATED WITH RESPONSE TO COMBINED INTRAVESICAL BACILLUS CALMETTE−GUERIN (BCG) AND ORAL SUNITINIB REGIMEN FOR TREATMENT OF HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)

The Journal of urology, 2019-04, Vol.201 (Supplement 4)

2019

Volltextzugriff (PDF)

Hormonal therapy for prostate cancer: past, present and future

Expert review of anticancer therapy, 2002-02, Vol.2 (1), p.37-47

2002

Volltextzugriff (PDF)

SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: A southwest oncology group study

The Prostate, 2002-09, Vol.52 (4), p.264-268

2002

Volltextzugriff (PDF)

Integrin alpha^sub 2^beta^sub 1^ ([alpha]^sub 2^[beta]^sub 1^) promotes prostate cancer skeletal metastasis

Clinical & experimental metastasis, 2013-07, Vol.30 (5), p.569

2013

Volltextzugriff (PDF)

KINETICS OF SERUM ANDROGEN NORMALIZATION AND FACTORS ASSOCIATED WITH TESTOSTERONE RESERVE AFTER LIMITED ANDROGEN-DEPRIVATION THERAPY IN NONMETASTATIC PROSTATE CANCER

The Journal of urology, 2008-08, Vol.180 (4), p.1432-1437

2008

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Aktive Filter

KollektionEZB Free E-Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(57)
Buchkapitel
(1)

Sprache

Englisch
(58)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(42)
Life Sciences & Biomedicine
(40)
Humans
(39)
Male
(36)
Aged
(25)
Urology & Nephrology
(25)
Middle Aged
(24)
Prostatic Neoplasms - Drug Therapy
(18)
Biological And Medical Sciences
(17)
Aged, 80 And Over
(15)
Medical Sciences
(15)
Oncology
(14)
Prostatic Neoplasms - Pathology
(13)
Prostate Cancer
(12)
Urology
(12)
Prostate-Specific Antigen - Blood
(10)
Tumors
(10)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)
Chemotherapy
(9)
Nephrology. Urinary Tract Diseases
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346)

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction

Inflammatory Bowel Disease and the Risk of Prostate Cancer

Phase II Evaluation of Early Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel Combined With Hormonal Therapy in Patients With High-risk Metastatic Prostate Adenocarcinoma: Southwest Oncology Group S0032

PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness

Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer

Educational Material on Prostate Cancer Screening is Overly Complex and Fails to Meet Recommended Layperson Readability Guidelines

The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data

A Sequential Treatment Approach to Myoinvasive Urothelial Cancer: A Phase II Southwest Oncology Group Trial (S0219)

Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421

A PROSPECTIVE ANALYSIS OF THE TIME TO NORMALIZATION OF SERUM ANDROGENS FOLLOWING 6 MONTHS OF ANDROGEN DEPRIVATION THERAPY IN PATIENTS ON A RANDOMIZED PHASE III CLINICAL TRIAL USING LIMITED HORMONAL THERAPY

A Double-Blind Randomized Crossover Study of Oral Thalidomide Versus Placebo for Androgen Dependent Prostate Cancer Treated With Intermittent Androgen Ablation

Kinetics of Serum Androgen Normalization and Factors Associated With Testosterone Reserve After Limited Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer

Southwest Oncology Group Phase II Study of Ispinesib in Androgen-Independent Prostate Cancer Previously Treated with Taxanes

Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study

Integrin alpha2beta1 (α2β1) promotes prostate cancer skeletal metastasis

Innovations and Challenges in Prostate Cancer: Summary Statement for the 6th Cambridge Conference

Phase II Open-Label Study of Oral Piritrexim in Patients with Advanced Carcinoma of the Urothelium Who Have Experienced Failure with Standard Chemotherapy

PD18-02 INCREASED URINARY VASCULAR ENDOTHELIAL GROWTH FACTOR D (VEGF-D) LEVELS ARE ASSOCIATED WITH RESPONSE TO COMBINED INTRAVESICAL BACILLUS CALMETTE−GUERIN (BCG) AND ORAL SUNITINIB REGIMEN FOR TREATMENT OF HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)

Hormonal therapy for prostate cancer: past, present and future

Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide

SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: A southwest oncology group study

Integrin alpha^sub 2^beta^sub 1^ ([alpha]^sub 2^[beta]^sub 1^) promotes prostate cancer skeletal metastasis

KINETICS OF SERUM ANDROGEN NORMALIZATION AND FACTORS ASSOCIATED WITH TESTOSTERONE RESERVE AFTER LIMITED ANDROGEN-DEPRIVATION THERAPY IN NONMETASTATIC PROSTATE CANCER

Aktive Filter

Suchergebnisse filtern